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ABSTRACT
The increase of bacterial strains resistant to most of the available antibiotics shows a need to explore
novel antibacterial targets to discover antimicrobial drugs. Bifunctional bacterial FAD synthetases (FADSs)
synthesise the flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These cofactors act in
vital processes as part of flavoproteins, making FADS an essential enzyme. Bacterial FADSs are potential
antibacterial targets because of differences to mammalian enzymes, particularly at the FAD producing site.
We have optimised an activity-based high throughput screening assay targeting Corynebacterium ammo-
niagenes FADS (CaFADS) that identifies inhibitors of its different activities. We selected the three best
high-performing inhibitors of the FMN:adenylyltransferase activity (FMNAT) and studied their inhibition
mechanisms and binding properties. The specificity of the CaFADS hits was evaluated by studying also
their effect on the Streptococcus pneumoniae FADS activities, envisaging differences that can be used to
discover species-specific antibacterial drugs. The antimicrobial effect of these compounds was also eval-
uated on C. ammoniagenes, S. pneumoniae, and Mycobacterium tuberculosis cultures, finding hits with
favourable antimicrobial properties.
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An important innovation gap in the discovering of antibiotics has
occurred during the last two decades1, with only five new classes
available and 51 new antimicrobials in clinical development2–4. In
addition, the selection of multi-drug resistant microorganisms5
encourages to search for new antimicrobial drugs capable of
inhibiting novel protein targets, such as those controlling the bio-
synthesis of essential biomolecules. Flavin mononucleotide (FMN)
and flavin adenine dinucleotide (FAD) are the cofactors of flavo-
proteins. All living organisms contain a great number of such pro-
teins and many of them are involved in essential functions6–8,
including protein folding9, electron transport in the respiratory
and photosynthetic chains10, b-oxidation of fatty acids11, nucleo-
tide synthesis or signal transduction12, among others. Lack, or low
levels, of FMN and FAD lead to the accumulation of apoflavopro-
teins, unable to perform the flavin-dependent functions, resulting
in the concomitant death of the cell or the organism13,14.
Prokaryotic bifunctional FAD synthetases (FADS) synthesise both
FMN and FAD, being therefore potential new antimicrobial tar-
gets15. Such hypothesis is sustained by several facts; (i) halting the
production of FMN and FAD prevents, from the very beginning, all
pathways that involve flavoproteins and flavoenzymes, (ii) in most
bacteria the only pathway for FMN and FAD biosynthesis occurs
with bifunctional FADS13,14, (iii) prokaryotic FADSs differ structur-
ally and biochemically from the mammalian proteins that trans-
form FMN into FAD16–19, so drugs that target these proteins are
likely to be selective for bacteria and (iv) the availability of struc-
tures of several bacterial FADSs facilitates the design of both
inhibitory drugs and activity assays20–22.
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Bacterial FADSs have both ATP:riboflavin kinase (RFK, EC
2.7.1.26) and ATP:FMN:adenylyltransferase (FMNAT, EC 2.7.7.2) activ-
ities, being the latter reversible (FAD pyrophosphorylase) in some
species17,23. FADSs synthesise FMN and FAD from riboflavin (RF, vita-
min B2) through two sequential reactions: RF is first phosphorylated
to FMN by the RFK activity, and then the FMNAT activity transfers an
adenylyl group from ATP to FMN producing FAD. These catalytic
activities are performed by two almost independent modules
(Supplementary Figure SD1). The C-terminus module produces FMN
from RF (named RFK module), while the N-terminal module trans-
forms FMN into FAD (FMNAT module). The RFK module shows
sequence and structural homology with the monofunctional eukary-
otic RFKs, while the FMNAT module does not present neither
sequence nor structural similarity with the proteins that synthesise
FAD in mammals16,21,24,25. Because the enzymes leading to FAD pro-
duction in prokaryotes and eukaryotes use different chemistry, and
belong to different structural families, potential inhibitors that spe-
cifically target the FMNAT module of bacterial FADSs are an interest-
ing option for the novel drug development15.
In this work, we have used as a model the FADS from the non-
pathogenic organism Corynebacterium ammoniagenes (CaFADS),
which is the best known model to characterise members of the
prokaryotic FADSs family17,24,26–30, in an activity-based high-
throughput screening (HTS) assay to find potential inhibitors. The
HTS hits were assayed to determine their specificity and potency
for the RFK and FMNAT activities. We also studied the kinetic
inhibition mechanism of the three most potent and selective
inhibitors of the FMNAT activity (FMNAT hits), as well as their
binding properties. Furthermore, considering the structural similar-
ity among CaFADS and the FADSs from the human pathogens
Streptococcus pneumoniae (included in the World Health
Organisation [WHO] priority list of antibiotic resistant pathogens;
SpnFADS) and Mycobacterium tuberculosis (the World’s leading
infectious killer; MtFADS), we explored the potential antimicrobial
effect of the FADS HTS hits in these microorganisms by determin-
ing their minimal inhibitory concentration (MIC). Some of the HTS
hits demonstrated high FADS inhibitory activity in vitro, but their
antimicrobial activity revealed that uptake of these compounds by
bacterial cells could be suboptimal. Collectively, our results valid-
ate our approach for discovering antimicrobials targeting bacterial
FADSs, and for identifying inhibitors that constitute a great start-
ing point for future developments of novel antimicrobials.
Methods
Protein purification and quantification
Recombinant CaFADS was overexpressed in BL21 (DE3) E. coli cells
and purified as previously described30. Recombinant SpnFADS was
overexpressed in E. coli strain Bl21 StarTM (DE3) and purified as
previously described23. Pure samples were dialysed against 20mM
PIPES, pH 7.0 and quantified using the theoretical extinction coeffi-
cients e279¼27.8mM1 cm1 and 28.8mM1 cm1 for CaFADS and
SpnFADS, respectively. The purity of each protein was tested by
15% SDS-PAGE.
Chemicals
The Prestwick Chemical LibraryVR , containing 1240 molecules
approved by the Food and Drugs Administration (FDA) and
European Medicines Agency (EMA), was selected for the HTS.
Compounds were dissolved in 100% DMSO at 10mM. All the HTS
hits were subsequently acquired from Sigma Aldrich, Prestwick or
Carbosynth and dissolved in 100% DMSO to prepare stock
solutions at 50 and 10mM. The purity of all compounds was
>95%, as determined by High performance liquid chromatography
(HPLC), thin layer chromatography (TLC), NMR, IR or basic titration.
Activity-based high-throughput screening for CaFADS
An activity-based HTS was performed on the 1240 compounds of
the Prestwick Chemical LibraryVR . The assays consisted in record-
ing the time dependent decrease in the fluorescence of the iso-
alloxazine ring, produced upon transformation of RF and FMN
into FAD, as a consequence of the fluorescence quenching in
this later flavin27. When either the RFK or the FMNAT activities
were inhibited, less FAD was produced and, consequently, the
fluorescence decrease registered in a specific time interval was
less pronounced. Measurements were carried out using a multi-
mode microplate reader, SynergyTM HT Biotek, with BRAND 96-
well plates pure GradeTM. To optimise the assay conditions, a
previous study was performed using constant concentrations of
RF, ATP and CaFADS (5, 50 and 0.4 mM, respectively) and
variable concentrations of MgCl2 (0.2–10mM) and DMSO
(0–12.5% v/v). Optimum conditions were 2.5% DMSO, 10mM
MgCl2 and sensitivity 70.
HTS reaction mixtures contained 5mM RF, 0.4 mM CaFADS,
10mM MgCl2, in PIPES 20mM, pH 7.0, 2.5% DMSO, and the corre-
sponding compound of the chemical library at a final concentration
of 250mM. Reactions were initiated through addition of 50 mM ATP,
being the final reaction volume 100 ml. Controls, which contained
the reaction mixture but not any chemical from the library, were
added both to the first and last columns of the plate. Flavin fluores-
cence in each well was registered at 25 C, every 50 s during 15min.
Excitation and emission wavelengths were 440 and 530 nm,
respectively. The slope of the resulting line, recorded between 0
and 6min, was calculated for every compound, and also for the
controls, as well as the fluorescence change per time unit (DF/Dt).
The compounds that decreased the reaction rate below the average
reaction rate of the controls minus the standard deviation could be
preselected as potential inhibitors, but we reduced further the cut-
off by selecting only those compounds inhibiting more than 50% of
the controls activity as HTS hits.
Identification of the activity inhibited by each of the HTS hits
The decreasing of the reaction rate by the presence of the HTS
hits might be consequence of the compounds inhibiting the RFK
activity, the FMNAT one, or both of them; also, it could be a false
positive due to the properties of pan assay interference com-
pounds (PAINS). To clarify this point, we first checked that there
were no PAINS among the HTS hits using the FAF-Drug4 web ser-
ver31. Then, the RFK and FMNAT reactions were individually
assayed in the presence of the HTS hits at 25 C. Reaction mixtures
contained 50 mM ATP, 5 mM RF, 0.4mM CaFADS in 20mM PIPES, pH
7.0, 0.8mM MgCl2, when assaying the RFK activity, and 50 mM ATP,
10 mM FMN, 0.4mM CaFADS in 20mM PIPES, pH 7.0, 10mM MgCl2
when measuring the FMNAT reaction. Each HTS hit was tested
again at 250mM for each of the two enzymatic reactions. Finally,
reactions were stopped by boiling the samples at 100 C for 5min,
and the precipitated protein was eliminated through centrifuga-
tion. The transformation of RF into FMN or FAD was evaluated
through flavins separation by HPLC, as previously described27.
Those HTS hits decreasing the FMNAT activity by more than 95%
of the controls, without significantly affecting the RFK activity
(rates over 75% those of the controls) were selected as FMNAT
hits for further assessment. When assaying the HTS hits against
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the FMNAT activity of SpnFADS, similar conditions were used but
samples contained 3mM sodium dithionite to maintain the flavin
in its reduced state23. Data were processed as previously
reported27. All the experiments were performed in triplicate.
Determination of the potency of FMNAT hits
To determine the IC50 values of the FMNAT hits, the FMNAT activ-
ity was assayed at different concentrations of each inhibitor
(0–100 mM range) and 25 C. Experiments were performed and
analysed through HPLC as described above. Positive controls
(without any hit compound) were included in every reaction set.
DMSO concentration was kept at 2.5% in all samples. All the
experiments were performed in triplicate.
Determination of the inhibition mechanism of CaFADS by
FMNAT hits 24, 27 and 31
The inhibition mechanism was further studied for the three
FMNAT hits that showed the lowest IC50 and minimal residual
FMNAT activities, namely, 24, 27 and 31. Reaction mixtures con-
taining 0–100 mM of each compound, 1–20 mM FMN and 400 mM
ATP were used when analysing the inhibitory effect of the com-
pound regarding the FMN substrate, while 5–400 mM ATP and
15mM FMN when analysing the effect of the inhibitor regarding
the ATP substrate. All the experiments were carried out in 20mM
PIPES, 10mM MgCl2, pH 7.0, 2.5% DMSO at 25 C, being the final
reaction volume 500ml. The reactions were initiated by addition of
CaFADS at a final concentration of 40 nM, followed by 1min
incubation. The flavin composition of the supernatant was ana-
lysed as previously described27. All the experiments were per-
formed in triplicate. The effect of the inhibitors on Km and Vmax
was determined by fitting the data sets to the Michaelis–Menten
model. Additionally, data were globally fit to Lineweaver–Burk
equations for competitive, uncompetitive, non-competitive or
mixed inhibition, yielding Ki, as well as Ki0 when applying, for each















































Thermodynamic characterisation of binding of hits 24, 27 and
31 through isothermal titration calorimetry (ITC)
ITC experiments were performed to characterise the protein’s affin-
ity for the selected compounds, as also the thermodynamic
parameters that drive the interaction. Experiments were carried
out in an AutoITC200 (MicroCal) thermostated at 25 C. In these
experiments, 400 mM of each compound were used to titrate
25mM CaFADS contained in a 200 mL cell. However, when satur-
ation of the protein was not reached, higher concentrations of
compounds were employed. The titrations were performed by
stepwise injections of the titrating compound. Up to 19 injections
of 2ml were added to the cell sample and mixed using a 1000 rpm
stirrer syringe. The compounds and the protein were dissolved in
20mM PIPES, pH 7.0, 10mM MgCl2 and degassed prior to titration.
DMSO was added to the protein and ligand samples, until reach a
final concentration of 3%. The association constant (Ka), the
enthalpy variation (DH) and the binding stoichiometry (N), were
obtained through non-lineal regression of the data to a model for
one or two independent binding sites, implemented in Origin 7.0
(OriginLab) as previously described27,29. The entropic contribution
(TDS), the Gibbs free energy (DG) and the dissociation constant
(Kd) were obtained through essential thermodynamic equations.
Docking of hits 24, 27 and 31 to the FMNAT module of CaFADS
The AutoDock4.2 software32–34 and the coordinates of a monomer
from CaFADS (PDB 2X0K)24 were used to obtain the interaction
models with 24, 27 and 31. The space sampling was defined using
a grid box of 90 points in each dimension, and placing the H57
NE atom of the FMNAT module as the grid box centre. The grid
size was 0.375 Å. The search was performed using the lamarkian
genetic algorithm, with a starting population of 150 individuals,
using 25,000,000 energy evaluations and 27,000 generations. The
24, 27 and 31 initial structures for the docking protocol were opti-
mised using the functional B3LYP with the basis set 6–31G (d,p)
and the gaussian09 software35. The structural poses with the low-
est docking score were selected and analysed.
Determination of the antibacterial activity of the HTS hits
The antimicrobial activity of the HTS hits was tested by the colori-
metric method of the resazurin microplate assay36 according to
broth microdilution method guidelines (CLSI; Clinical and
Laboratory Standards Institute). Serial 2-fold dilutions of the HTS
hits were performed in BHI medium, in 96-well microtiter plates,
with a final volume of 100ml per well. Subsequently, liquid cul-
tures of C. ammoniagenes ATCC 6872 in logarithmic phase were
adjusted to 106 CFU/ml in BHI broth, and 100 ml of this suspension
were added to each well, making a final inoculum of 5 105 CFU/
ml. Plates were incubated 16 h at 37 C. 30ml of 0.1mg/ml resa-
zurin solution were then added to each well, and results were
observed after 4 h of incubation at 37 C. Resazurin (blue) is an
indicator of bacterial growth, since metabolic activity of bacteria
reduces it to resorufin (pink). The minimum inhibitory concentra-
tion (MIC) is the lowest concentration of compound that does not
change the resazurin colour from blue to pink.
Similarly, the HTS hits were also assayed at 37 C against M.
tuberculosis ATCC 27,294 and S. pneumoniae ATCC 49619 cells. In
these experiments the initial cell concentration was also 5 105
CFU/ml, and plates were incubated for 10 h (S. pneumoniae), and
6 days (M. tuberculosis) before addition of resazurin. Results were
observed after incubation with resazurin 4 h and two days for S.
pneumoniae and M. tuberculosis, respectively. In these experiments,
culture media were; Middlebrook 7H9 (Difco) supplemented with
10% ADC (0.2% dextrose, 0.5% V fraction BSA and 0.0003% bovine
catalase) (BD Difco) and with 0.5% glycerol (Scharlau) for M. tuber-
culosis growth, and BHI supplemented with 4% FBS (Gibco) for S.
pneumoniae growth.
Statistics
Results are expressed as the mean± the standard deviation (SD) or
as the mean± the standard error (SE) of the regression. When indi-
cated, one-way analysis of variance (ANOVA) was performed to
determine statistical significance.
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Results
Identification of potential inhibitors of the CaFADS activities
through HTS
To identify potential inhibitors of the CaFADS activities we
designed the activity-based HTS assay described in the methods
section, which allowed to determine rates for the transformation
of RF into FAD (via the FMN intermediate) in each one of the plate
wells. Wells containing chemicals of the library and decreasing
reaction rates relative to the controls (absence of chemicals) were
preselected as containing compounds that are potential inhibitors
of at least one of the CaFADS activities. Thus, among the 1240
compounds of the chemical library, 140 (13.5%) reduced the
CaFADS activity levels below the mean of the positive controls
minus twice its standard deviation, and of them, 37 (3.6%)
reduced the positive controls average rate for FAD formation in a
factor higher than 0.5 (Figure 1). Those 37 compounds were
selected as the HTS hits (Supplementary Chart SD1).
Effect of the HTS hits on the RFK and FMNAT activities of
CaFADS
We then move to identify which one of the activities (RFK or
FMNAT), and in which extension, was affected by each one of
these 37 HTS hits. With this aim, we assayed the effect of the HTS
hits both on the CaFADS RFK and FMNAT activities. Figure 2 and
Table 1 summarise the results. Comparison of Figure 2(A,B) shows
that, in general and under the assay conditions, the 37 HTS hits
produced a stronger deleterious effect on the FMNAT activity (all
decreased the activity of the controls in more than 50%) than on
the RFK one. The FMNAT module of CaFADS does not have
sequence or structural homology with the mammalian protein but
the RFK module belongs to the eukaryotic RFKs family. Therefore,
we decided to continue the study with the HTS hits that inhibit
the FMNAT activity, since they are more likely to be specific to the
bacterial proteins. Thus, we choose the HTS hits that decreased
the FMNAT activity below 5% of that of the controls, but main-
tained over 75% the RFK activity (Figure 2, Table 1). Thus, among
(2)\(11), tiratricol (15), benzbromarone (17), oxantel pamoate (19),
Chicago sky blue 6B (24), gossypol (27), flunixin meglumine (31)
and oxaprozin (43) (Chart 1) were selected as FMNAT hits. It is
Figure 2. Effect of the HTS hits on the RFK and FMNAT activities of CaFADS.
Residual (A) RFK and (B) FMNAT activities when assayed in the presence of
250lM of the 37 HTS hits. In (A), the columns below the dashed line present
statistical significant inhibition by the corresponding hit (p< 0.002, 67% remain-
ing activity) related to the control CaFADS RFK activity. In (B), all hits produce
statistical significant inhibition (p< 0.0001, dashed line) when compared with the
controls of the CaFADS FMNAT activity. Solid lines indicate 75 and 5% of the con-
trol RFK and FMNAT activities, respectively. The HTS hits displaying<5% and
>75% of the control FMNAT and RFK activities, respectively, were selected for
further study. Experiments carried out in 20mM PIPES, pH 7.0, 2.5% DMSO at
25 C, with 7.5lM RF, 350lM ATP, 0.8mM MgCl2 (for the RFK activity) or 15lM
FMN, 350lM ATP, 10mM MgCl2 (for the FMNAT activity) (n¼ 3; mean± SD).
Figure 1. Activity-based high throughput screening (HTS) for the discovery of
inhibitors of the RFK and/or the FMNAT activities of CaFADS. (A) Example of the
flavin fluorescence evolution over time for three of the identified hits and for
control assays. Reaction mixtures were incubated at 25 C and contained 5 mM RF,
50mM ATP, 0.4mM CaFADS, 10mM MgCl2, in PIPES 20mM, pH 7.0, 2.5% DMSO.
The black symbols and lines correspond to kinetic traces at wells containing
library compounds at 250mM, while grey ones correspond to control wells. (B)
Initial velocities (Dfluorescence/s) for the reactions in each of the wells of a HTS
plate. Data from wells containing chemical library compounds are in black while
controls are in grey. The solid line represents the average velocity obtained for
the positive controls of the reaction and the dotted lines are the average velocity
plus and minus the standard deviation. The letters and numbers indicate the pos-
ition of the well in the plate (row and a column respectively) for each specific
selected measurement. A bold dashed line indicates 50% the rates of controls.
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Table 1. RFK and FMN residual activities of CaFADS in the presence of the HTS hits.
% Residual RFK activity
 5 5–50 50–75 	75
% Residual FMNAT activity
5 9, 29, 33, 37 14,47 2, 11, 15, 17, 19, 24, 27, 31, 43
5–50 35 38 22,32 1, 3, 4, 5, 6, 7, 8, 10, 12, 13, 16,
18, 25, 28, 39, 40, 44, 46
	50 – – – –
Values measured at 25 C, in 20mM PIPES, pH 7.0, 2.5% DMSO and 0.8 or 10mM MgCl2 when assaying the RFK or the FMNAT activ-
ities, respectively. The final concentration of each HTS hit was 250 lM and saturating concentrations of all the substrates were used.
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Chart 1. Chemical structures of compounds selected as FMNAT hits for CaFADS.
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worth noticing that although some of these compounds are
apparently structurally related with other of the HTS hits, slight
differences in functional groups and geometries induce different
enzymatic responses in the FMNAT or RFK activities. This is a fact
of particular interest when developing specific inhibitors.
To rate the power of these 9 FMNAT hits as inhibitors of the
CaFADS FMNAT activity, their half maximal inhibitory concentra-
tions (IC50) and the remaining activity at 50mM of each compound
were determined (Figure 3, Table 2). The 9 compounds yielded
IC50 values in the micromolar range, reducing by more than half
the activity of the controls. Considering both their IC50 value and
residual activity, the most potent inhibitors were 24 (IC50
¼ 0.4 ± 0.1mM), 27 (IC50 ¼ 0.5 ± 0.1mM) and 31 (IC50 ¼ 6.6 ± 0.6mM).
These three compounds produce residual activities below 25% of
the controls. Compound 43 also showed high inhibitory potency,
but due to its low solubility in the working buffer it was
discarded.
The inhibition mechanisms of 24, 27 and 31
To determine the inhibition mechanism of the hits 24, 27 and 31,
we measured the FMNAT activity of CaFADS in the presence of
increasing concentrations of each compound. Considering that
this is a bi-substrate activity, for each compound we carried out
two set of experiments at; (i) saturating ATP and different FMN
concentrations, and (ii) saturating FMN and increasing ATP con-
centrations. Then we fit our experimental data to the
Michaelis–Menten model, obtaining Km and kcat values. The ana-
lysis of the evolution of these constants on the hits concentra-
tions, together with the corresponding Lineawever–Burk plots
[representation of data as double inverses and fit to Equations
(1–4)] (Figure 4, Supplementary Figures SD2 and SD3,
Supplementary Table SP1) allowed identifying the inhibitory mech-
anisms of the 24, 27 and 31 hits, as well as the corresponding
inhibition constants (Ki or, Ki and Ki0) (Table 3). The experiments
carried out at saturating ATP (varying the FMN concentrations),
revealed that the three compounds are strong non-competitive
inhibitors of the CaFADS FMNAT activity regarding the FMN sub-
strate (Ki values around 0.08 mM, Table 3). Nevertheless, when
using a constant and saturating FMN concentration but varying
the ATP concentration, their inhibition mechanisms differ among
them. 24 is a strong ATP uncompetitive inhibitor (Ki ¼ 0.08 ± 0.
03 mM), therefore, it is able to bind the CaFADS-ATP complex and
reduce the amount of enzyme that is available to react. 27 is a
strong competitive inhibitor regarding the ATP substrate (Ki¼ 0.
06 ± 0.01mM), while 31 is a considerably poorer mixed inhibitor.
Thus, 31 is able to bind to both the free enzyme and the CaFADS-
ATP complex, although binding constants indicate that binding to
free CaFADS is preferred (Ki 3.5 ± 1.0mM versus Ki0 18.4 ± 4.0 mM,
Table 3).
Binding of 24, 27 and 31 to CaFADS
The interaction of CaFADS with compounds 24, 27 and 31 was
characterised using ITC. This is a very powerful technique
because first the shape of the thermograms informs us about
the number of binding sites related to the thermodynamic
nature of binding. Then, fitting of experimental data to the equa-
tions describing binding models allow determining thermo-
dynamic binding parameters, as well as binding stoichiometry at
each of the different binding sites. Thus, analysis of our ITC titra-
tions indicates that the three compounds bind the enzyme at, at
least, one binding site (Figure 5(A), Table 4). Thus, we identified
in CaFADS a unique binding site of moderate-low affinity for 31
(N
 1, Kd¼ 30.9 ± 2.8mM) and two binding sites of high and simi-
lar affinity for 27 (N
 2, Kd,av¼ 0.7 ± 0.07mM, this Kd,av value is an
average value, since the similarity between the two binding sites
prevents them to be distinguished). These 27 and 31 binding
sites are expected to be located at the enzyme FMNAT domain,
since that is the inhibited activity. The interaction between the
hit 24 and the enzyme resulted more complicated, because our
ITC data indicate that compound 24 binds to the protein at
three sites. Two of them show similar and strong affinity
(Kd,av¼ 1.1 ± 0.1mM) and therefore, we suggest that they might
be located at the FMNAT module, since that is the activity
mainly inhibited by compound 24. The third site for 24 binding
has lower affinity (Kd¼ 161 ± 20 mM). Since this compound also
mildly inhibits the RFK activity, we presume this third binding
site may be at the RFK module. All bindings here characterised
(with the only exception of the low affinity binding site for 24)
are favoured by the enthalpic contribution (Figure 5(B), Table 4).
This suggests a net gain of H-bonding and ion-pair interactions
and indicates specific binding interactions. Regarding the
entropic contribution to the binding free energy, it is small and
favourable for 24 and 27, and only slightly unfavourable for 31
(Figure 5(B), Table 4). However, it drives the binding of 24 to the
Figure 3. Dose–response curves for the FMNAT activity of CaFADS in the pres-
ence of representative hits. Values derived from these representations are
included in Table 2. Experiments performed at 25 C in 20mM PIPES, pH 7.0,
10mM MgCl2, 2.5% DMSO, with 15lM FMN and 350lM ATP (n¼ 3, mean± SD).
Table 2. Effect of the FMNAT hits on the FMNAT activity of CaFADS.
FMNAT hit Residual activitya (%) IC50
b (lM)
2 41.1 ± 5.2 8.9 ± 1.0
11 34.6 ± 4.9 9.0 ± 1.3
15 45.3 ± 4.2 40.7 ± 3.9
17 33.5 ± 10.1 12.8 ± 3.4
19 43.3 ± 3.9 20.8 ± 2.6
24 3.6 ± 0.2 0.4 ± 0.1
27 6.9 ± 0.8 0.5 ± 0.1
31 24.5 ± 1.9 6.6 ± 0.6
43c 20.3 ± 5.2 1.0 ± 0.5
Experiments carried out at 25 C, in 20mM PIPES, pH 7.0, 10mM MgCl2 at satu-
rating FMN and ATP. All samples contained 2.5% DMSO (n¼ 3, mean ± SD).
aRemaining activity in the presence of 50 lM of each compound. All data show
statistical significance differences when compared with activity in the com-
pound absence (p< 0.0001).
bCompounds assayed in the 0–100 lM concentration range.
cThis compound shows very low water solubility, so it was discarded to continue
the study even though its good properties.
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RFK module (site 3 Figure 5(B)), revealing that it might be non-
specific and that could occur due to the compound hydrophobi-
city and rigidity37.
To investigate how the FMNAT module of CaFADS accommo-
dates these compounds, we performed a computational protein-
ligand docking (Figure 6 and Supplementary Figure SD4). In the
highest-scoring docking mode, as well as for the best five poses
(purple molecule in Figure 6(B), Supplementary Figure SD4,
respectively), 241 (1 indicates the first molecule of 24 docked) is
situated in the substrates binding pockets (Figure 6A)24. One of
the 241 moieties binds through one of its sulphates to S164 and
H31. 241 is in addition H-bonded to the N125 catalytic base
17, as
well as to Y106, T127 and N131 at the loop that forms the upper
flavin ring binding site (Figure 6(B)). Since our ITC data suggest
two binding sites for compound 24 at the FMNAT module, we
carried out an additional docking analysis to identify the second
site, 242 (pink molecule in Figure 6(B)), using as receptor our
highest-scoring FADS:241 model. Considering the binding
energies (Table 4) this site is expected to be less populated, but
given that 24 is an ATP uncompetitive inhibitor, the docking
binding energy could improve if we consider the ATP substrate
presence instead of the 241 molecule. Additionally, it is worth
noting that in the presence of substrates or products, the 24
binding conformations might differ from the ones presented
here. In the most favourable docking poses, the first molecule of
27 bound to the protein (271) is H-bonded by T127 and the
N125 catalytic base at the binding site of the ATP phosphates17
(purple molecule in Figure 6(C) and SD4), in agreement with 27
being an ATP competitive inhibitor. Because two binding sites
were again predicted by ITC at the FMNAT site, we carried out a
second docking using as receptor the highest-scoring FADS:271
model. 272 is stabilised by H-bonds with the N-terminal of the
a6n helix, T165 and R168, at the ATP binding site entrance (pink
molecule in Figure 6(C)). We observed direct interaction between
the two 27 molecules, and 272 somehow resembling the 241
binding (purple molecule in Figure 6(B)). For 31, we only carried
Figure 4. Hit 27 as an inhibitor of the FMNAT activity of CaFADS. Michaelis–Menten plots at different concentrations of 27 and saturation (A) of ATP and (B) of FMN.
Lineaweaver–Burk representations with global fit to (C) non-competitive inhibition at saturating ATP and (D) competitive inhibition at saturating FMN. Reaction rates
obtained in 20mM PIPES, pH 7.0, 10mM MgCl2, at 25 C, with 15lM FMN and 10–450lM ATP (FMN saturating) or with 350lM ATP and 0.5–20lM FMN (ATP saturat-
ing). All samples contained 2.5% DMSO (n¼ 3, mean± SD).
Table 3. Inhibition constants and mechanisms of the best FMNAT hits relative to the FMNAT activity of CaFADS.
Saturating ATP Saturating FMN
Ki (lM) Inhibition mechanism Ki (lM) K
’
i (lM) Inhibition mechanism
24 0.07 ± 0.01 Non-competitive 0.08 ± 0.03 – Uncompetitive
27 0.08 ± 0.01 Non-competitive 0.06 ± 0.01 – Competitive
31 0.09 ± 0.03 Non-competitive 3.5 ± 1.0 18.4 ± 4.0 Mixed
Experimental data recorded at 25 C in 20mM PIPES, pH 7.0, 10mM MgCl2 and 2.5% DMSO. Data obtained by globally fitting the
experimental data to the corresponding Lineweawer–Burk inhibition model.
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out the flunixin docking, given that this compound is the bio-
active agent of 31 and meglumine is the excipient. The best
poses for 31 binding are suggested at the ATP binding site
(Figure 6(D) and SD4), stabilised by a H-bond with H31. This
binding is coherent with the ATP mixed inhibition mechanism of
31. In all cases, the H-bond interactions explain the favourable
enthalpic binding contributions revealed by ITC, while the favour-
able entropic contributions can be attributed to the expelling of
Figure 5. Thermodynamic analysis of the binding of the selected FMNAT hits to CaFADS. (A) Calorimetric titrations for the 24, 27 and 31 compounds. The upper panels
show the thermograms for the interaction and the lower panels show the corresponding binding isotherms with integrated heats. (B) Thermodynamic dissections of
the interaction of CaFADS with each of the selected compounds. The binding Gibbs energy (DG), enthalpy (DH) and entropy (TDS) are represented in black, grey and
white bars, respectively. Experiments were carried out at 25 C, in 20mM PIPES, pH 7.0, 10mM MgCl2 and 3% DMSO.
Table 4. Thermodynamic parameters for the interaction of CaFADS with the hits 24, 27 and 31.
Hit N Kd (lM) DG (kcal/mol) DH (kcal/mol) TDS (kcal/mol) Docking DG b (kcal/mol)
24
Site 1–2 
 2 1.1 ± 0.1a 8.1 ± 1.0a 4.2 ± 0.5a 3.9 ± 0.5a 8.2 ± 0.5/-4.2 ± 0.4
Site 3 
 1 161 ± 20 5.2 ± 0.7 18.4 ± 2.2 23.6 ± 1.9 n.d.c
27 
 2 0.7 ± 0.07a 8.4 ± 0.9a 3.1 ± 0.1a 5.3 ± 0.4a 11.9 ± 0.1/9.1 ± 0.1
31 
 1 30.9 ± 2.8 6.2 ± 0.6 7.2 ± 0.4 1.1 ± 0.1 6.59 ± 0.1
ITC experiments performed at 25 C, in PIPES 20mM, pH 7.0, 10mM MgCl2, 3% DMSO.
aThese parameters correspond to average values for the binding of two hit molecules.
bDocking score for the best pose, with standard deviation for the best five poses.
cNot calculated.
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structural water molecules from the binding cavities, particularly
at the substrates binding sites.
Effect of the HTS hits on the RFK and FMNAT activities of
SpnFADS
To determine whether the 37 HTS hits were specific for CaFADS or
might have effect on other similar bacterial FADS family members,
we tested their effects on the RFK and FMNAT activities of the
also bimodular and bifunctional SpnFADS. Eleven of the 37 HTS
hits inhibited either the RFK or the FMNAT activities of SpnFADS
(Table 5). However, most compounds exhibited IC50 in the high
micromolar range (>65mM). Only fluvastatin sodium salt (37) for
the FMNAT activity, and thonzonium bromide (9) and 27 for the
RFK one showed IC50 lower than 10mM. 37 (IC50¼ 7± 1mM) and 9
(IC50¼ 6± 1mM) inhibit completely the corresponding activity, but
the residual RFK activity with 27 was too high to be considered as
a good inhibitor.
Effect of selected HTS hits on different bacterial cells
To assess the effect of the HTS hits on the growth of different
bacteria, we determined their MIC (Table 6). Bacterial cells of C.
ammoniagenes, M. tuberculosis and S. pneumoniae were grown
in the presence of increasing concentrations of the selected HTS
hits. Among the 37 HTS hits, only twelve, six and nine com-
pounds inhibited, respectively, the growth of C. ammoniagenes,
M. tuberculosis and S. pneumoniae. Among these, only 9, benze-
thonium chloride (14), methyl-benzethonium chloride (29), alexi-
dine dihydrochloride (33) and verteporfin (47) showed MIC
values for C. ammoniagenes lower than 2 mM, while 17, 24,
diethylstilbestrol (32) and dienestrol (35) show values between 2
and 16 mM (Table 6). Interestingly, the compounds that pre-
sented better properties against the CaFADS FMNAT activity (24,
27 and 31) have a poor growth inhibitory effect on the bacter-
ial cells (24 and 27 have MIC
 32 and 64mM, respectively,
whereas the MIC of 31 was>64mM). Nonetheless, it is worth to
notice that 9, 14, 29, 33 and 47 show in common the consider-
abl ability to inhibit both of the CaFADS enzymatic activities as
well as to greatly affect the C. ammoniagenes growth (Table 1,
Figure 7). Regarding M. tuberculosis growth, sulfasalazine (8), 9,
24 and 29 produced mild effects on cell growth, but only 14
and 33 showed MIC values below 8 mM. Table 6 summarises the
effect of some selected compounds on S. pneumoniae, indicat-
ing that 9, 14, 29 and 33 inhibit moderately its growth.
(A) (B)
(C) (D)
Figure 6. Docking models for the binding conformations of the selected FMNAT hits to the CaFADS FMNAT module. (A) Model of the theoretical placement of sub-
strates. ATP in violet, Mg2þ as a green dot and FMN in yellow. Data from (24). Best docking pose of (B) FADS:241 and FADS:241:242 models (241 in violet, 242 in pink),
(C) FADS:271 and FADS:271:272 models (271 in violet, 272 in pink), and (D) FADS:31 (31 in violet, docking corresponds only to the flunixin bioactive part of 31, meglu-
mine is the excipient). Side-chains of key residues are shown as CPK sticks with carbons in wheat. H-bonds are indicated as dashed lines. The protein is shown as a car-
toon, having the FMNAT and RFK modules coloured in grey and green, respectively. Docking was performed using Autodock4.2.
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Discussion
Validation of the HTS protocol
Here we have designed and optimised an enzymatic activity-based
HTS protocol to discover specific inhibitors for CaFADS. In this
protocol, the direct evaluation of the FMNAT enzymatic activity
allows for the selection of species-specific inhibitors38,39. Our HTS
protocol is simple, effective and consumes little protein (1.5 ng/
compound against the 5 mg/compound required for some differ-
ential scanning fluorescence-based HTSs). Our protocol monitors
directly the activity of the enzyme that we want to inhibit (Figure
1(A)), therefore, minimises the number of false positives and
PAINS. In addition, because the chemicals in the library are
approved drugs, their toxicity in mammalian cells is expected to
be limited. The 37 HTS hits obtained (3.6% of the chemical library)
were further assayed against the RFK and FMNAT activities of
CaFADS. Nine of the HTS hits (when assayed at 250 mM) almost
completely inhibited the FMNAT activity without practically
affecting the RFK one (Table 1). Because the FMNAT activity of
CaFADS appeared as a preferred target, due to the different active
site regarding eukaryotic enzymes, we further assessed the inhibi-
tory power of these FMNAT hits.
Inhibitors targeting the FMNAT activity of CaFADS
We choose the three FMNAT hits that showed the lowest IC50 and
residual activity (24, 27 and 31, 8% of the HTS hits) (Table 2) to
further determine their binding affinities and inhibition mecha-
nisms. Chicago Sky Blue 6B (CSB), here 24, is an allosteric inhibitor
of the Macrophage Inhibitor Factor, and shows promising in vivo-
effects for the treatment of spinal cord injury40. Additionally, 24
can act as an anticancer drug through the specific inhibition of
Rad 51, as well as a potential resource for Alzheimer disease treat-
ment by inhibiting the binding of b-amyloid to the prion pro-
tein41,42. Furthermore, the inhibition of vesicular glutamate
transporters by 24 attenuates expressions of behavioural sensitiza-
tion43. In our study, CSB is the most potent inhibitor of the
CaFADS FMNAT activity, as shown by its lowest values of residual
activity and IC50 (Table 2), targeting the free enzyme as well as
the FMN-protein and ATP-protein complexes (Table 3,
Supplementary Figure SD2). Moreover, 24 binds to both enzyme
modules being the binding to the FMNAT site highly favourable
and enthalpically driven (Table 4, Figure 5). This is an advantage
for an inhibitor, since high binding enthalpy denotes lots of spe-
cific interactions44.
Gossypol, here 27, was used some years ago in China as a mas-
culine contraceptive45, however, its side effects stopped its
pharmacological use. More recently, 27 has demonstrated anti-
cancer effects through the inhibition of antiapoptotic proteins
belonging to the Bcl-2 family and of molecules implicated in
tumour progression46,47. Additionally, 27 inhibits the HIV-1 replica-
tion in vitro48. 27 is a potent inhibitor of the CaFADS FMNAT activ-
ity, as shown by the low IC50 and residual FMNAT activity (Table
2), while does not affect the RFK one (Table 1, Figure 2). This com-
pound competes with ATP for its binding at the FMNAT site (Table
3, Figures 4 and 6(C)). The lower Kd value for 27 when compared
with that of FMN29, makes the inhibitor a preferred ligand for
CaFADS.
31, or flunixin meglumine, is a non-steroidal anti-inflammatory
drug, analgesic and antipyretic extensively used in horses, pigs
and cattle49–51. This fact guarantees that 31 can be used securely
in mammals. In this study, 31 arises as a mixed inhibitor of the
CaFADS FMNAT activity. This is in agreement with our docking
model and its small size, envisaging that binding of this com-
pound might coexist with binding of substrates or products in
non-competent conformations. Although 31 is the less potent
inhibitor of the three here characterised (Table 2, Figure 3), its
binding thermodynamic properties, together with its bio-security
in mammals, reveals its potentiality as a drug precursor.
Our docking models supply additional details about the
molecular inhibition mechanisms of 24, 27 and 31. Because 27 is a
competitive inhibitor it occupies the active site substituting ATP,
as demonstrated with the best docking poses (Figure 6(C)).
However, the way in which 24 and 31 inhibit the FMNAT activity
is not obvious. The 31 binding conformation (Figure 6(D)) could
be affected by the ATP ligand, and, given the small size of 31, it
could coexist with ATP in the active site, causing the previously
described intricate mechanism. In presence of ATP, the 24 binding
conformation should be different to the one of our FADS:241
model, because ATP has to displace 24 from the binding site,
given that 24 partially occupies it24. It is probable that with ATP in
Table 5. Effect of selected HTS hits on the RFK and FMNAT activities of
SpnFADS.
RFK activity FMNAT activity
HTS hit Res. activitya (%) IC50
b (lM) Res. activitya (%) IC50
b (lM)
1 100 ± 15 – 0 ± 0 69 ± 5
2 78 ± 10 >100 100 ± 12 –
7 92 ± 10 >100 0 ± 0 73 ± 7
9 0 ± 0 6 ± 1 7 ± 1 78 ± 6
10 100 ± 12 – 0 ± 0 68 ± 7
14 100 ± 10 – 63 ± 7 >100
24 84 ± 9 >100 0 ± 0 70 ± 6
25 81 ± 8 >100 0 ± 0 70 ± 6
27 25 ± 4  6 ± 1 0 ± 0  51 ± 6
29 71 ± 8 >100 0 ± 0  64 ± 5
33 26 ± 3  33 ± 4 93 ± 11 >100
37 96 ± 10 >100 0 ± 0  7 ± 1
38 40 ± 5  88 ± 6 68 ± 7  >100
43 32 ± 3  14 ± 2 100 ± 15 –
All the experiments were carried out at 25 C, in 20mM PIPES pH 7.0, 10mM
MgCl2 at saturating concentrations of FMN and ATP and in the presence of 2.5%
DMSO. (n¼ 3, mean ± SD).
aRemaining activity in the presence of 100lM of each compound. Data showing
statistical significance differences when compared with activity in the absence
of compound (p< 0.0001; 0.0021> p> 0.0001; 0.033> p> 0.0021).
bCompounds assayed in the 0–100 lM concentration range.
Table 6. Minimal inhibitory concentration (MIC) of selected HTS hits against dif-
ferent microorganisms.
HTS hit C. ammoniagenes (lM) M. tuberculosis (lM) S. pneumoniae (lM)
1 >64 >64 >64
2 >64 >64 >64
9 2 16 1-2
11 >64 >64 >64
14 0.25 8 2
15 32 >64 64
17 8 >64 >64
24 16–32 16–32 >64
27 64 >64 >64
29 0.125 16–32 1
31 32–64 >64 >64
32 8 >64 64
33 0.125 2–4 0.5
35 16–32 >64 64
37 >64 >64 >64
38 32 >64 16–32
47 2–4 8 4
The FMNAT hits are shown in italics. Compounds were assayed in the
0.125–64 lM range.
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the active site, and taking into account the large size of this mol-
ecule, 24 only interacts with the active site via the N-terminal of
the a6n helix (pink molecule in Figure 6(B)) and the flexible loop
L4n that forms the external and entry part of the FMNAT sub-
strates cavities23,24. In this way, the 24 sulphates would be able to
coordinate the magnesium ion to potentially induce a change in
the ATP phosphates orientation, negatively affecting their orienta-
tion for the FMNAT activity as well as the entry and exit of the
reaction ligands.
Inhibition of other bacterial FADS by CaFADS FMNAT hits
S. pneumoniae causes more than 25% of the cases of community-
acquired pneumonia52, generating more deaths than any other
vaccine-preventable bacterial disease. M. tuberculosis causes tuber-
culosis, the most common cause of death among infectious dis-
eases53. SpnFADS has as similar native structure to CaFADS
(Supplementary Figure SD1), while the MtFADS sequence shows
45% identity with CaFADS and 59% of conservation30. Since the
attempts to produce stable purified MtFADS have so far failed, we
considered CaFADS a good model for MtFADS, as reported for
other proteins of these two genera54. Thus, we tested the effect of
the CaFADS HTS hits on the RFK and FMNAT activities of SpnFADS.
We can find that only 30% of the HTS hits have inhibitory effects
on SpnFADS, and the high values of residual activities and IC50
reveal that they are worse inhibitors for SpnFADS (Table 5).
Nevertheless, among the HTS hits, 9, 27, 37 and 43 are interesting
inhibitors of SpnFADS (Table 5). 27 and 43, which did not inhibit
the CaFADS RFK activity (Table 1), have an important effect on the
SpnFADS one. 9, inhibits both SpnFADS activities (Table 5). This
compound is a monocationic detergent that has been commonly
used in cortisporin-TC ear drops to help penetration of active
ingredients through cellular debris. Additionally, 9 inhibits vacuolar
ATPase, showing cytotoxic effects at concentrations higher than
10mM55. It is also an inhibitor of the RANK-L induced osteoclast
formation56. 37, inhibited both CaFADS activities, but only affects
the FMNAT one in SpnFADS. 37 inhibits the HMG-CoA reductase,
being used to treat hypercholesterolemia57. 37 has positive effects
in myocardial fibrosis by favouring ACE2 expression, and also
modestly inhibits replication of the hepatitis C virus58,59. 43 is
used as analgesic (inhibits anandamide hydrolase in neurons) and
as anti-inflammatory60,61, acting as a no selective cyclooxygenase
inhibitor. Additionally, it inhibits NF-jb in activated monocytes,
being a promising drug for the treatment of rheumatoid arth-
ritis62. Regarding the three FMNAT hits of CaFADS: 24 has a poor
inhibitory effect on SpnFADS (Table 5), which might be of interest
as selective inhibitor; 27 inhibits both CaFADS and SpnFADS activ-
ities (Tables 1 and 5), appearing as a broad inhibitor of FADS; and
31 has no effect on SpnFADS (Table 5), indicating the specificity of
this compound for CaFADS.
Recent studies23,28,63–65 revealed important differences in
catalysis among bifunctional FADS, probably related to dissimilar-
ities in the active site conformation during catalysis. This is consist-
ent with the differential inhibitory mechanisms of the HTS hits
against CaFADS and SpnFADS, as observed in the present work.
Such mechanistic variations could determine the binding or the
inhibitory capability of the hits. These observations highlight the
potentiality of our method to find selective drugs targeting a
specific protein of a particular microorganism. The development
of such species-selective drugs is of great importance for the treat-
ment of infections by avoiding undesired side-effects on normal
microbiota of the host66, and for minimising the selection of resist-
ant bacterial strains.
Antimicrobial activity of the CaFADS FMNAT hits
Finally, we also tested the inhibitory activity of the best FMNAT
hits on the growth of C. ammoniagenes, S. pneumoniae and M.
tuberculosis cultures. 24 shows moderate effects on the C. ammo-
niagenes and M. tuberculosis growth (Table 6, Figure 7). However,
Figure 7. Venn diagrams for the HTS hits effects on C. ammoniagenes and S. pneumoniae. (A) HTS hits that inhibit the RFK (dark grey circle) and FMNAT (medium grey
circle) activities of CaFADS as well as the growth of C. ammoniagenes cells (pale grey circle). (B) HTS hits that inhibit the RFK (dark grey circle) and FMNAT (medium
grey circle) activities of SpnFADS and the S. pneumoniae cellular growth (pale grey circle). In (A), The hits whose inhibition potency was experimentally assessed in this
study (inhibit the FMNAT activity without affecting the RFK one) are highlighted in bold. The hits surrounded by a circle, both in (A) and (B), also inhibit the prolifer-
ation of M. tuberculosis.
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it does not inhibit the pneumococci growth. 27 and 31 do not
inhibit the growth of C. ammoniagenes, S. pneumoniae or M. tuber-
culosis cells. This might be due to their inability to enter in the
bacterial cell, or because efflux pumps eject them once in the bac-
terial cytoplasm. Tools to favour their bactericide effects can be
obtained by deriving second generation hits, using vehiculization
systems to move drugs across the membrane, or using efflux
pumps inhibitors67–69. In this context, we remark that inhibition of
FAD synthesis in M. tuberculosis could have an immediate impact
in current antituberculosis drug discovery programmes.
Benzothiazinones are antituberculosis compounds that block ara-
binan synthesis by targeting the flavoprotein decaprenylphos-
phoryl-b-D-ribose 2'-epimerase DprE170. It is expected that the
antituberculosis activity of benzothiazinones, which are currently
in phase I clinical trials4, could be enhanced by FADS inhibition, in
a synergistic manner. Among the other FMNAT hits, only 15, 17
and 31 show mild inhibitory activity on the growth of C. ammonia-
genes, but do not have an effect on S. pneumoniae and M. tubercu-
losis cultures (Figure 7).
We find five HTS hits (9, 14, 29, 33 and 47) as strong inhibitors
of the C. ammoniagenes growth (Table 6, Figure 7). These five HTS
hits also inhibit the growth of S. pneumoniae (Table 6, Figure 7),
while only the first four mildly affect M. tuberculosis. Noticeably,
these five HTS hits are good inhibitors of both CaFADS activities
(Table 1, Figure 7). 9 and 29 also appear as potent inhibitors of
the SpnFADS RFK and/or FMNAT activities. The effect of the other
three compounds as SpnFADS inhibitors is milder, suggesting
mechanisms that do not involve FADS in preventing cell prolifer-
ation. Overall, our results suggest that targeting both activities of
bifunctional FADSs can be a strategy in the discovery of new anti-
bacterial drugs. Thus, the non-selective antimicrobial properties of
9 and 29 seem interesting tools to be explored.
In this context, and despite all compounds in the library are
approved by FAD and EMA, it remains for future studies to test
the effect of the most promising compounds on the homologous
human proteins and cells. In addition, future studies should also
focus on the improvement of these compounds regarding
potency, selectivity, pharmacokinetics and drug-likeness.
Conclusions
The FMNAT activity of bifunctional FADS enzymes is a potential
antimicrobial target for drug discovery. The transformation of FMN
into FAD is performed by different catalytic mechanisms in prokar-
yotes and eukaryotes, and the FMN and FAD deficiency inactivates
an important number of flavoproteins. In this work, we have opti-
mised an activity-based HTS that can be used to discover new
antibacterial drugs, targeting the RFK and/or FMNAT activities of
bifunctional FADSs. Our method allows identifying bacterial FADS
inhibitors with different levels of selectivity regarding the inhib-
ition of bacterial growth. The method is fast, effective and requires
small protein quantities. We have confirmed that bacterial FADS
are promising species-selective drug targets. Among the 1240
compounds from the Prestwick Chemical LibraryVR , 37 inhibited
CaFADS, and three were potent inhibitors of its FMNAT (but not
of the RFK) activity. Two of these compounds were not species-
selective because they also affected SpnFADS, but the third one,
31, was selective for CaFADS versus SpnFADS. These three com-
pounds are promising as non-selective or selective inhibitors at
the enzyme level. However, they do not produce observable anti-
microbial effects, suggesting that they do not reach inhibitory con-
centrations at the intracellular level, possibly due to a poor
uptake, efficient efflux or in vivo fast degradation. Nevertheless,
some HTS hits show good antimicrobial properties, probably due
to the inhibition of both RFK and FMNAT activities of FADS.
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